1-12 of 12
Raul Ayala
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5991: Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers

Neil A. O'Brien, Martina S. McDermott, Brendan M. O'Boyle, Justin A. Hilf, Oliver Loson, Kevin Chau, Weiping Jia, Naeimeh Kamranpour, Tong Luo, Raul Ayala, Shawnt Issakhanian, John A. Glaspy, Brian M. Stoltz, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5991.
https://doi.org/10.1158/1538-7445.AM2023-5991
Published: 04 April 2023
View article titled, Abstract 5991: Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
Journal Articles

Abstract 6258: The discovery and preclinical characterization of the potent covalent KRASG12C inhibitor UCT-001024

Tristin E. Rose, Brendan M. O'Boyle, Justin A. Hilf, Emma L. Baker-Tripp, Zhengao Feng, Kevin Yang, Michael D. Bartberger, Oliver C. Losón, Neil A. O'Brien, Martina S. McDermott, Naeimeh Kamranpour, Weiping Jia, Tong Luo, Raul Ayala, John Glasby, Brian M. Stoltz, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6258.
https://doi.org/10.1158/1538-7445.AM2023-6258
Published: 04 April 2023
View article titled, Abstract 6258: The discovery and preclinical characterization of the potent covalent KRAS<sup>G12C</sup> inhibitor UCT-001024
Journal Articles

Abstract 6254: The discovery and preclinical characterization of the SAM-competitive PRMT5 inhibitor UCT-000445

Martina S. McDermott, Neil A. O'Brien, Brendan O'Boyle, Michael Bartberger, Oliver C. Losón, Kevin Chau, Ella Schwab, Jenny Hong, Jiaying Zhou, Chuhong Hu, Tong Luo, Raul Ayala, John Glasby, Brian M. Stoltz, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6254.
https://doi.org/10.1158/1538-7445.AM2023-6254
Published: 04 April 2023
View article titled, Abstract 6254: The discovery and preclinical characterization of the SAM-competitive PRMT5 inhibitor UCT-000445
Journal Articles

Abstract 4044: Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers

Neil A. O'Brien, Martina S. McDermott, Brendan M. O'Boyle, Corey M. Reeves, Michael Bartberger, Oliver Loson, Kevin Chau, Jenny J. Hong, Weiping Jia, Naeimeh Kamranpour, Tong Luo, Raul Ayala, Athena M. Madrid, John A. Glaspy, Brian M. Stoltz, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4044.
https://doi.org/10.1158/1538-7445.AM2023-4044
Published: 04 April 2023
View article titled, Abstract 4044: Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers
Journal Articles

Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

Neil A. O'Brien, Holly K. Huang, Martina S. McDermott, Athena Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB197.
https://doi.org/10.1158/1538-7445.AM2022-LB197
Published: 15 June 2022
View article titled, Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies
Journal Articles

Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models

Neil A. O'Brien, Martina SJ McDermott, Dylan F. Conklin, Alex Gaither, Tong Luo, Raul Ayala, Suruchi Salgar, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3825.
https://doi.org/10.1158/1538-7445.AM2019-3825
Published: 01 July 2019
View article titled, Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models
Journal Articles

Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy

Neil A. O'Brien, Dylan Conklin, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ondrej Kalous, Erika Von Euw, Sara A. Hurvitz, Emmanuelle DiTomaso, Faye Su, Ronald Linnartz, Stefan Scherer, Samit Hirawat, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4150.
https://doi.org/10.1158/1538-7445.AM2017-4150
Published: 01 July 2017
View article titled, Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy
Journal Articles

Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer

Neil A O'Brien, Dylan Conklin, Michaela Ching, Luo Tong, Raul Ayala, Shawnt Issakhanian, Sara A Hurvitz, Emmanuelle di Tomaso, Ronald Linnartz, Richard S Finn, Samit Hirawat, Dennis J Slamon
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-05-04.
https://doi.org/10.1158/1538-7445.SABCS14-P5-05-04
Published: 01 May 2015
View article titled, Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer
Journal Articles

Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer

Neil A. O'Brien, Emmanuelle D. Tomaso, Raul Ayala, Luo Tong, Shawnt Issakhanian, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4756.
https://doi.org/10.1158/1538-7445.AM2014-4756
Published: 01 October 2014
View article titled, Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer
Journal Articles

Imaging Mitogen-Activated Protein Kinase Function in Xenograft Models of Prostate Cancer

Romyla Ilagan, Jill Pottratz, Kim Le, Liqun Zhang, Steven G. Wong, Raul Ayala, Meera Iyer, Lily Wu, Sanjiv S. Gambhir, Michael Carey
Journal: Cancer Research
Cancer Res (2006) 66 (22): 10778–10785.
https://doi.org/10.1158/0008-5472.CAN-05-3577
Published: 15 November 2006
View article titled, Imaging Mitogen-Activated Protein Kinase Function in Xenograft Models of Prostate Cancer
Open the PDF for Imaging Mitogen-Activated Protein Kinase Function in Xenograft Models of Prostate Cancer in another window
Journal Articles

Bioluminescence imaging of AR and MAPK activity in androgen independent prostate cancer xenografts

Romyla S. Ilagan, Jill K. Pottratz, Kim H. Le, Steven G. Wong, Raul Ayala, Dennis J. Slamon, Michael F. Carey
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 459.
Published: 01 May 2005
View article titled, Bioluminescence imaging of AR and MAPK activity in androgen independent prostate cancer xenografts
Journal Articles

Overexpression of AKT2/Protein Kinase Bβ Leads to Up-Regulation of β1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells

M. Jane Arboleda, John F. Lyons, Fairooz F. Kabbinavar, Mark R. Bray, Bryan E. Snow, Raul Ayala, Mordechai Danino, Beth Y. Karlan, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2003) 63 (1): 196–206.
Published: 01 January 2003
View article titled, Overexpression of AKT2/Protein Kinase Bβ Leads to Up-Regulation of β1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells
Open the PDF for Overexpression of AKT2/Protein Kinase Bβ Leads to Up-Regulation of β1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells in another window